ClinPoint Trials is seeking adults and children over 4 years of age with asthma to participate in a research study.
Why is this study being conducted?
Currently, there are several treatment options that can be used as needed to prevent or relieve asthma symptoms. Although these treatments are commonly used and can be effective, doctors continue to research treatment options for patients with asthma through clinical studies.
In this study, doctors want to learn more about the inhaled study medication (which is a combination of budesonide and albuterol). Separately, these two medications are well-established treatments that have been widely used for asthma. This study medication will be compared to another well-established inhaled medication (albuterol along) to learn about the safety and effectiveness of the study medication in relieving symptoms of asthma in adults and children 4 years of age or older.
What will happen in this study?
You (or your child) will continue to take regular daily asthma medicine to control asthma symptoms and will be given study medication only when asthma worsens to use in addition to your (or your child’s) regular asthma medication.
You or your child will visit our clinic at least 9 times over a minimum 6-month period, with possible additional visits every 3 months until the study is completed.
You will receive all study-related procedures and the study medication at no cost. You will also be reimbursed for your time participating in this study.
Who is eligible to participate in this study?
To be eligible for this study, you or your child must be:
At least 4 years of age or older
Diagnosed with asthma for at least 1 year
Taking medications for asthma
Experiencing asthma exacerbation (asthma attacks) in the past 12 months that required additional treatment and/or hospitalization
Other criteria may apply to determine if you are eligible.
To learn more about this study, or to find out if you (or your child) will qualify, call our office at 972-937-1640 or click here to submit a contact form.